FBIO - Fortress Biotech Inc Stock Price, Fair Value and News

1.92USD+0.16 (+9.09%)Delayed

Market Summary

USD1.92+0.16

Delayed

9.09%

FBIO Stock Price

View Fullscreen

FBIO RSI Chart

FBIO Valuation

Market Cap

37.2M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

0.44

EV/EBITDA

0.35

Price/Free Cashflow

-0.34

FBIO Price/Sales (Trailing)

FBIO Profitability

EBT Margin

-175.35%

Return on Equity

1.4K%

Return on Assets

-33.11%

Free Cashflow Yield

-296.92%

FBIO Fundamentals

FBIO Revenue

Revenue (TTM)

85.1M

Rev. Growth (Yr)

4.84%

Rev. Growth (Qtr)

-34.67%

FBIO Earnings

Earnings (TTM)

-54.5M

Earnings Growth (Yr)

28.42%

Earnings Growth (Qtr)

-66.15%

Breaking Down FBIO Revenue

Last 7 days

15.0%

Last 30 days

8.5%

Last 90 days

3.2%

Trailing 12 Months

276.5%

How does FBIO drawdown profile look like?

FBIO Financial Health

Current Ratio

1.33

Debt/Equity

-4.59

Debt/Cashflow

-6.11

FBIO Investor Care

Shares Dilution (1Y)

122.85%

Diluted EPS (TTM)

-8.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	85.1M	0	0	0
2023	64.2M	62.7M	81.0M	84.5M
2022	70.2M	73.0M	74.4M	75.7M
2021	44.3M	52.7M	64.3M	68.8M
2020	43.1M	43.3M	43.0M	45.6M
2019	27.5M	29.9M	34.5M	36.6M
2018	152.9M	67.1M	25.4M	26.9M
2017	20.4M	110.8M	156.7M	149.8M
2016	1.0M	3.3M	4.2M	18.3M
2015	0	0	0	863.0K
2014	0	0	0	0
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fortress Biotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	jin david	acquired	3,998	1.7	2,352	chief financial officer
Jan 05, 2024	rosenwald lindsay a md	bought	118,770	2.3754	50,000	president, ceo & chairman
Jan 01, 2024	harvey jimmie	acquired	-	-	6,666	-
Jan 01, 2024	klein dov	acquired	-	-	6,666	-
Jan 01, 2024	lorenz kevin	acquired	-	-	3,333	-
Jan 01, 2024	rowinsky eric k	acquired	-	-	6,666	-
Jan 01, 2024	rosenwald lindsay a md	acquired	-	-	216,465	president, ceo & chairman
Jan 01, 2024	weiss michael s	acquired	-	-	216,465	see remarks
Jan 01, 2024	hoenlein malcolm	acquired	-	-	3,333	-
Jan 01, 2024	lu lucy	acquired	-	-	3,333	-

Which funds bought or sold FBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-84,759	-	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-258,785	-	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	new	-	42,006	42,006	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-1,793,960	-	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-18,651	36,932	-%
May 15, 2024	MORGAN STANLEY	reduced	-45.05	-7,084	4,074	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-1.78	-821	1,542	-%
May 15, 2024	Altium Capital Management LP	sold off	-100	-1,219,420	-	-%
May 15, 2024	Integrated Wealth Concepts LLC	added	99.34	9,833	40,132	-%
May 15, 2024	Cetera Investment Advisers	sold off	-100	-40,451	-	-%

Are Funds Buying or Selling FBIO?

Are funds buying FBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FBIO

No. of Funds

Unveiling Fortress Biotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	4.2%	372,562	SC 13G/A
Jan 03, 2024	rosenwald lindsay a md	15.3%	2,813,905	SC 13D/A
Nov 21, 2023	weiss michael s	7.6%	1,130,520	SC 13D/A
Nov 21, 2023	rosenwald lindsay a md	17.5%	2,597,440	SC 13D/A
Feb 14, 2023	katz daryl	4.76%	6,052,975	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	7.3%	7,968,056	SC 13G/A
Feb 09, 2023	vanguard group inc	4.70%	5,104,407	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	9.6%	9,086,005	SC 13G/A
May 07, 2021	blackrock inc.	5.0%	4,814,223	SC 13G/A
Feb 16, 2021	nantahala capital management, llc	9.3%	8,680,909	SC 13G

Recent SEC filings of Fortress Biotech Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13D/A	13D - Major Acquisition
May 17, 2024	S-3	S-3
May 17, 2024	144	Notice of Insider Sale Intent
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 17, 2024	4	Insider Trading
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	424B3	Prospectus Filed

Peers (Alternatives to Fortress Biotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Fortress Biotech Inc News

Latest updates

Fortress Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-34.7%	13,030,000	19,946,000	34,752,000	17,386,000	12,429,000	16,404,000	16,528,000	18,886,000	23,925,000	21,100,500	18,276,000	21,085,000	17,843,000	11,587,000	13,749,000	9,475,000	9,457,000	12,918,000	11,130,000	9,772,000	9,250,000
Costs and Expenses	25.4%	49,596,000	39,559,000	48,510,000	67,491,000	71,296,000	71,038,000	67,262,000	69,812,000	71,195,000	-	82,148,500	71,008,000	60,700,000	41,604,000	38,052,000	32,518,000	34,853,000	34,446,000	41,511,000	32,312,000	34,540,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,540,000
S&GA Expenses	-20.7%	17,941,000	22,611,500	21,733,000	24,439,000	25,341,000	28,199,000	30,139,000	29,048,000	26,270,000	-	27,698,000	22,221,000	19,382,000	17,542,000	15,808,000	15,383,000	14,456,000	15,519,000	14,330,000	14,339,000	13,443,000
R&D Expenses	-	24,839,000	-	-	-	39,506,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-0.2%	-1.65	-1.65	-2.49	-3.18	-3.11	-2.65	-2.05	-2.11	-2.16	-2.21	-2.25	-1.46	-1.75	-2.08	-2.03	-2.12	-2.16	-2.18	-2.57	-2.80	-
Interest Expenses	22.4%	1,658,000	1,355,000	1,459,000	2,246,000	2,885,000	2,824,000	2,608,000	2,431,000	1,556,000	-	1,893,000	1,686,000	1,669,000	1,670,000	1,535,000	3,504,000	1,556,000	1,609,000	1,468,000	1,438,000	1,438,000
Income Taxes	-100.0%	-	379,000	141,000	52,000	-104,000	449,000	-	59,000	107,000	-	-188,000	157,000	504,000	-	500,000	-	-	-	-2,388,500	-	-
Earnings Before Taxes	100.0%	-	-28,605,000	-10,583,000	-	-	-56,996,000	-53,060,000	-	-	-	-	-	-	-	-	-	-	-	-32,955,000	-24,970,000	-27,480,000
EBT Margin	0.7%	-1.75	-1.77	-2.64	-3.40	-3.32	-2.82	-2.21	-2.25	-2.30	-2.34	-2.39	-1.60	-1.95	-2.32	-2.26	-2.37	-2.35	-2.36	-2.78	-3.00	-
Net Income	-66.1%	-15,417,000	-9,279,000	-5,045,000	-24,776,000	-21,537,000	-26,948,000	-22,511,000	-21,356,000	-15,760,000	-	-31,565,000	-20,781,000	-3,535,000	-8,822,000	-5,295,000	-15,547,000	-13,314,000	-12,370,000	-15,492,000	-12,762,000	-13,098,000
Net Income Margin	10.7%	-0.64	-0.72	-0.97	-1.53	-1.44	-1.14	-1.23	-1.23	-1.00	-0.92	-0.94	-0.60	-0.63	-0.97	-1.02	-1.32	-1.25	-1.25	-1.09	-1.43	-
Free Cashflow	27.3%	-25,415,000	-34,963,000	-16,780,000	-33,325,000	-43,220,000	-47,935,000	-44,253,000	-41,731,000	-48,197,000	-40,653,000	-40,653,000	-22,157,000	-36,150,000	-22,146,000	-21,184,000	-23,371,000	-18,635,000	-22,418,000	-25,942,000	-16,764,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.7%	165	168	151	181	264	294	324	364	408	397	408	418	391	333	296	269	229	226	222	227	201
Current Assets	-0.4%	117	117	98.00	128	202	230	258	299	341	346	301	320	318	266	238	200	159	156	166	164	137
Cash Equivalents	6.1%	86.00	81.00	72.00	78.00	152	178	208	249	288	308	253	275	290	235	218	183	153	153	151	165	133
Inventory	3.7%	11.00	10.00	11.00	12.00	13.00	14.00	15.00	16.00	16.00	10.00	12.00	14.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-5.8%	6.00	7.00	7.00	7.00	12.00	13.00	14.00	14.00	14.00	15.00	14.00	13.00	12.00	12.00	12.00	12.00	13.00	12.00	12.00	12.00	12.00
Liabilities	1.6%	169	166	164	197	244	244	222	216	214	171	195	170	147	136	120	152	153	154	147	137	150
Current Liabilities	3.3%	88.00	85.00	97.00	129	129	128	106	105	103	101	103	71.00	54.00	52.00	37.00	57.00	52.00	46.00	47.00	36.00	49.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	18.00	13.00	11.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	18.00	13.00	11.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-117.5%	-3.94	23.00	17.00	19.00	20.00	42.00	101	148	194	226	212	248	244	197	176	117	75.00	73.00	75.00	90.00	51.00
Retained Earnings	-2.2%	-710	-694	-685	-680	-655	-634	-607	-584	-563	-547	-515	-495	-491	-482	-477	-461	-448	-436	-420	-407	-394
Additional Paid-In Capital	2.2%	733	717	702	699	693	676	669	662	661	656	608	603	597	583	574	521	485	462	446	439	415
Shares Outstanding	28.4%	19.00	15.00	9.00	9.00	9.00	7.00	6.00	6.00	6.00	7.00	5.00	5.00	5.00	6.00	5.00	5.00	4.00	5.00	4.00	3.00	-
Minority Interest	-28.7%	-26.96	-20.96	-29.92	-34.45	-17.99	8.00	40.00	70.00	96.00	117	120	140	138	97.00	79.00	56.00	38.00	46.00	49.00	58.00	30.00
Float	-	-	-	-	53.00	-	-	-	66.00	-	-	-	254	-	-	-	174	-	-	-	71.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	27.3%	-25,387	-34,935	-16,779	-33,291	-43,220	-47,844	-43,273	-41,424	-46,860	-38,696	-21,696	-34,460	-21,688	-20,486	-23,892	-17,412	-21,892	-25,052	-16,264	-28,320	-25,325
Share Based Compensation	31.1%	4,857	3,704	4,377	4,217	4,731	5,506	6,837	5,081	5,563	7,037	4,326	4,350	3,773	3,132	3,171	3,748	3,400	2,765	3,741	3,373	3,309
Cashflow From Investing	100.0%	-	-63.00	4,999	-2,039	-5,000	-391	-893	-307	-21,337	53,353	-7,541	-4,840	-458	-1,567	-2,758	-1,063	-1,776	310	-3,750	-611	24,148
Cashflow From Financing	-36.1%	27,859	43,618	-2,685	-30,381	22,187	18,618	3,746	2,991	49,964	38,941	6,966	24,395	78,692	37,015	46,832	65,810	22,753	27,155	5,552	61,894	52,113
Dividend Payments	-100.0%	-	180	185	185	186	186	188	188	187	187	187	188	187	187	50.00	-	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.00	-82.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FBIO Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Product revenue, net	$ 13,030	$ 12,165
Collaboration revenue		181
Other revenue		48
Net revenue	13,030	12,429
Operating expenses
Cost of goods sold - product revenue	6,816	6,449
Research and development	24,839	35,276
Research and development - licenses acquired		4,230
Selling, general and administrative	17,941	25,341
Total operating expenses	49,596	71,296
Loss from operations	(36,566)	(58,867)
Other income (expense)
Interest income	833	1,036
Interest expense and financing fee	(2,602)	(4,296)
Gain (loss) on common stock warrant liabilities	(667)	6,678
Other income (expense)	(21)	304
Total other income (expense)	(2,457)	3,722
Net loss	(39,023)	(55,145)
Net loss attributable to non-controlling interests	23,606	33,608
Net loss attributable to Fortress	(15,417)	(21,537)
Net loss attributable to common stockholders	$ (17,731)	$ (23,545)
Net loss per common share attributable to common stockholders - basic	$ (1.03)	$ (3.47)
Weighted average common shares outstanding - basic	17,151,945	6,792,376
Related Party
Revenue
Revenue - related party		$ 35

FBIO Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 83,774	$ 80,927
Accounts receivable, net	9,799	15,222
Inventory	10,580	10,206
Prepaid expenses and other current assets	12,071	10,500
Total current assets	116,548	117,022
Property, plant and equipment, net	6,128	6,505
Operating lease right-of-use asset, net	16,462	16,990
Restricted cash	2,063	2,438
Intangible asset, net	19,473	20,287
Other assets	3,971	4,284
Total assets	164,645	167,526
Current liabilities
Accounts payable and accrued expenses	76,379	73,562
Income taxes payable	843	843
Common stock warrant liabilities	689	886
Operating lease liabilities, short-term	2,601	2,523
Partner company convertible preferred shares, short-term, net	4,021	3,931
Partner company installment payments - licenses, short-term, net	3,000	3,000
Other short-term liabilities	163	163
Total current liabilities	87,696	84,908
Notes payable, long-term, net	61,420	60,856
Operating lease liabilities, long-term	17,619	18,282
Other long-term liabilities	1,847	1,893
Total liabilities	168,582	165,939
Commitments and contingencies (Note 14)
Stockholders' equity (deficit)
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share	3	3
Common stock, $0.001 par value, 200,000,000 shares authorized, 19,375,343 and 15,093,053 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	19	15
Additional paid-in-capital	733,290	717,396
Accumulated deficit	(710,287)	(694,870)
Total stockholders' equity attributed to the Company	23,025	22,544
Non-controlling interests	(26,962)	(20,957)
Total stockholders' equity (deficit)	(3,937)	1,587
Total liabilities and stockholders' equity (deficit)	164,645	167,526
Related Party
Current assets
Other receivables - related party	$ 324	$ 167

About Fortress Biotech Inc

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

CEO	Dr. Lindsay Allan Rosenwald
WEBSITE	fortressbiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	187

Fortress Biotech Inc Frequently Asked Questions

What is the ticker symbol for Fortress Biotech Inc? What does FBIO stand for in stocks?

FBIO is the stock ticker symbol of Fortress Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fortress Biotech Inc (FBIO)?

As of Fri May 17 2024, market cap of Fortress Biotech Inc is 37.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FBIO stock?

You can check FBIO's fair value in chart for subscribers.

What is the fair value of FBIO stock?

You can check FBIO's fair value in chart for subscribers. The fair value of Fortress Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fortress Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fortress Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether FBIO is over valued or under valued. Whether Fortress Biotech Inc is cheap or expensive depends on the assumptions which impact Fortress Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FBIO.

What is Fortress Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FBIO's PE ratio (Price to Earnings) is -0.68 and Price to Sales (PS) ratio is 0.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fortress Biotech Inc's stock?

In the past 10 years, Fortress Biotech Inc has provided 0.013 (multiply by 100 for percentage) rate of return.